ES2521841B1 - Diagnostic procedure and prognosis of chronic kidney disease in a human subject - Google Patents
Diagnostic procedure and prognosis of chronic kidney disease in a human subject Download PDFInfo
- Publication number
- ES2521841B1 ES2521841B1 ES201330663A ES201330663A ES2521841B1 ES 2521841 B1 ES2521841 B1 ES 2521841B1 ES 201330663 A ES201330663 A ES 201330663A ES 201330663 A ES201330663 A ES 201330663A ES 2521841 B1 ES2521841 B1 ES 2521841B1
- Authority
- ES
- Spain
- Prior art keywords
- chronic kidney
- kidney disease
- human subject
- prognosis
- diagnostic procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 abstract 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 abstract 1
- 229960003080 taurine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Procedimiento y kit de diagnóstico y pronóstico de enfermedad renal crónica y de enfermedad cardiovascular asociada a enfermedad renal crónica en un sujeto humano, que comprende determinar en una muestra las concentraciones de al menos uno de los compuestos seleccionados del grupo compuesto por 5-oxoprolina, glutamato, guanidoacetato, alfa-fenilacetilglutamina, taurina, trimetilamina N-óxido (TMNO), homocisteína, leucina, treonina y citrato, determinar si los valores de dichas concentraciones son superiores o inferiores a los valores de referencia de pacientes sanos.Diagnostic and prognostic procedure and kit for chronic kidney disease and cardiovascular disease associated with chronic kidney disease in a human subject, comprising determining in a sample the concentrations of at least one of the compounds selected from the group consisting of 5-oxoproline, glutamate , guanidoacetate, alpha-phenylacetylglutamine, taurine, trimethylamine N-oxide (TMNO), homocysteine, leucine, threonine and citrate, determine whether the values of these concentrations are higher or lower than the reference values of healthy patients.
Description
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330663A ES2521841B1 (en) | 2013-05-08 | 2013-05-08 | Diagnostic procedure and prognosis of chronic kidney disease in a human subject |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330663A ES2521841B1 (en) | 2013-05-08 | 2013-05-08 | Diagnostic procedure and prognosis of chronic kidney disease in a human subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2521841A1 ES2521841A1 (en) | 2014-11-13 |
| ES2521841B1 true ES2521841B1 (en) | 2015-09-09 |
Family
ID=51866519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201330663A Expired - Fee Related ES2521841B1 (en) | 2013-05-08 | 2013-05-08 | Diagnostic procedure and prognosis of chronic kidney disease in a human subject |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2521841B1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20032528A1 (en) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | USE OF CYSTINE OR CISTEIN FOR PREVENTION AND THE |
| WO2005094813A1 (en) * | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | Medicine for kidney disorder |
| CN102203619B (en) * | 2008-10-31 | 2015-12-16 | 圣文森特医院悉尼有限公司 | Forecasting Methodology in chronic kidney disease |
-
2013
- 2013-05-08 ES ES201330663A patent/ES2521841B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2521841A1 (en) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014018970A8 (en) | SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS | |
| JP2014144959A5 (en) | ||
| EP2971132A4 (en) | TISSUE AND BLOOD MIARN BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS AND PREDICTIVE POTENTIAL OF METASTASES IN COLORECTAL CANCER | |
| EP3159695A3 (en) | Methods for diagnosing pancreatic cancer | |
| MY193895A (en) | Combination test for colorectal cancer | |
| HK1247250A1 (en) | Context dependent diagnostics test for guiding cancer treatment | |
| ES2684758T3 (en) | Procedure to diagnose liver fibrosis | |
| WO2015006657A8 (en) | Method for the diagnosis and prognosis of cancer | |
| GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
| ES2521841B1 (en) | Diagnostic procedure and prognosis of chronic kidney disease in a human subject | |
| WO2014153661A8 (en) | Method for detecting and monitoring bone loss | |
| RU2014113841A (en) | METHOD FOR EARLY DIAGNOSTICS OF ENDOGENOUS INTOXICATION | |
| KR102235718B9 (en) | Biomarker composition and kit for bladder cancer diagnosis or prognosis analysis, and diagnostic method using the same | |
| RU2014119323A (en) | A method for predicting the risk of atrial fibrillation in patients with cardiovascular disease | |
| UA85502U (en) | Method for evaluating prognosis of chronic renal disease with chronic pyelonephritis and hypertension | |
| RU2014119325A (en) | A method for predicting the risk of chronic atrial fibrillation in patients with cardiovascular disease | |
| EP3396379A4 (en) | BIOMARKER FOR DIAGNOSIS, PROGNOSIS AND MONITORING COLORECTAL CANCER WITH EARLY APPEARANCE | |
| UA111794U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| RU2014150315A (en) | A method for diagnosing a predisposition to the development of atherosclerosis | |
| UA109990U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| UA111850U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| UA113364U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| UA110057U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| UA108307U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT | |
| UA110089U (en) | METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2521841 Country of ref document: ES Kind code of ref document: B1 Effective date: 20150909 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20230926 |